New Jersey Congressman Tom Kean Jr. Opens Up About His Depression Diagnosis

Overview

New Jersey Congressman Tom Kean Jr. has publicly disclosed his treatment for depression following a four-month absence from Congress.

Background

Depression is a significant mental health condition affecting millions of Americans, including over 48 million individuals currently receiving treatment.

Data Highlights

No numerical or trial data was provided in the source material.

Key Findings

• Tom Kean Jr. was absent from Congress for four months due to depression.
• He emphasized the physical and emotional aspects of depression in his speech.
• Kean's absence complicated legislative processes for House Republican leaders.
• He stated that there is no set timeline for healing from depression.
• Kean plans to run for reelection despite his health challenges.

Clinical Implications

The disclosure of mental health issues by public figures can help reduce stigma and encourage others to seek help.

Conclusion

Tom Kean Jr.'s openness about his depression highlights the challenges faced by many in high-pressure roles.

Related Resources & Content

1. Associated Press, AP News, 2023 -- New Jersey Congressman Tom Kean Jr. Opens Up About His Depression Diagnosis
2. The ASCO Post — Coexisting With Cancer and Depression
3. Stat News — Congress must hold RFK Jr. accountable after hearings
4. ADA News — ADA thanks Senate Committee for support of mental health bill
5. ADA News — Three ADPAC-supported member dentists reelected to Congress
6. Clinical Practice Guidelines and Recommendations | ACP
7. Mental Health Clinical Practice Guidelines - VA/DOD Clinical Practice Guidelines
8. January 2026 exceptional surveillance of depression in adults: treatment and management (NICE guideline NG222)
9. Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis - ScienceDirect
10. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial - PubMed
11. Oral Ketamine for Treatment Resistant-Depression
12. Compass Pathways - Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
13. Recommendation: Depression and Suicide Risk in Adults: Screening | United States Preventive Services Taskforce
14. Depression in adults - Symptoms, diagnosis and treatment | BMJ Best Practice US